Press Release – New York, NY – July 24, 2026 – Sichenzia Ross Ference Carmel LLP announced that it represented D. Boral Capital as the exclusive placement agent for the recently priced $3.8 million registered direct offering of NanoViricides, Inc. (NYSE American: NNVC), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape.
The SRFC team was led by partner Ross Carmel, with associates Jesse Blue and Matthew Palumbo.